Novel COVID-19 Vaccine May Provide Protection for Cancer Patients with B-cell Deficiencies; Peptide-Based Vaccine Induces T Cell-Dependent Immune Response; Results Presented at AACR Annual Meeting

CoVac-1, a new vaccine against SARS-CoV-2, induced T-cell immune responses in 93 percent of patients with B-cell deficiencies, including many patients with leukemia and lymphoma, according to results presented at the AACR Annual Meeting 2022, held April 8-13 in New Orleans. Over 19,000 scientists and physicians are registered for the AACR (American Association for Cancer Research) conference, with ~80% (~15,200) attending in person and ~20% (~3,800) attending virtually. The AACR has over 50,000 members worldwide. “To our knowledge, CoVac-1 is currently the only peptide-based vaccine candidate specifically developed and evaluated for immunocompromised patients,” said Juliane Walz, MD, senior author of the study and a Professor of Peptide-Based Immunotherapy at the University Hospital Tübingen in Germany.

Login Or Register To Read Full Story